{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:12Z","timestamp":1791235392937,"version":"4.1.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00109-024-02424-w","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T07:03:51Z","timestamp":1708585431000},"page":"465-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging therapeutic targets in systemic sclerosis"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-740X","authenticated-orcid":false,"given":"Steven","family":"O\u2019Reilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"1","key":"2424_CR1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y et al (2015) Systemic sclerosis Nature Reviews Disease Primers 1(1):15002","journal-title":"Systemic sclerosis Nature Reviews Disease Primers"},{"issue":"10103","key":"2424_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. The Lancet 390(10103):1685\u20131699","journal-title":"The Lancet"},{"issue":"4","key":"2424_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","volume":"16","author":"M Hughes","year":"2020","unstructured":"Hughes M et al (2020) Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 16(4):208\u2013221","journal-title":"Nat Rev Rheumatol"},{"key":"2424_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.semcdb.2019.12.007","volume":"101","author":"Y Asano","year":"2020","unstructured":"Asano Y, Varga J (2020) Rationally-based therapeutic disease modification in systemic sclerosis: novel strategies. Semin Cell Dev Biol 101:146\u2013160","journal-title":"Semin Cell Dev Biol"},{"issue":"26","key":"2424_CR5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"},{"issue":"24","key":"2424_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490\u20132498","journal-title":"JAMA"},{"issue":"6","key":"2424_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.1780270607","volume":"27","author":"AD Roumm","year":"1984","unstructured":"Roumm AD et al (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis.\u00a0Quantification, subtyping, and clinical correlations. Arthritis Rheum 27(6):645\u2013653","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2424_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.37738","volume":"65","author":"T H\u00fcgle","year":"2013","unstructured":"H\u00fcgle T et al (2013) Tumor necrosis factor\u2013costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 65(2):481\u2013491","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2424_CR9","first-page":"1202","volume":"19","author":"O Ishikawa","year":"1992","unstructured":"Ishikawa O, Ishikawa H (1992) Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 19(8):1202\u20131206","journal-title":"J Rheumatol"},{"issue":"4","key":"2424_CR10","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/ar3066","volume":"12","author":"N Higashi-Kuwata","year":"2010","unstructured":"Higashi-Kuwata N et al (2010) Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 12(4):R128","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2424_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/art.39602","volume":"68","author":"M Ciechomska","year":"2016","unstructured":"Ciechomska M et al (2016) Histone demethylation and Toll-like receptor 8-dependent cross-talk in monocytes promotes transdifferentiation of fibroblasts in systemic sclerosis via Fra-2. Arthritis Rheumatol 68(6):1493\u20131504","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2424_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug B et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79(3):379\u2013386","journal-title":"Ann Rheum Dis"},{"key":"2424_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13","journal-title":"F1000Prime Rep"},{"issue":"7","key":"2424_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.41243","volume":"72","author":"R Bhandari","year":"2020","unstructured":"Bhandari R et al (2020) Profibrotic activation of human macrophages in systemic sclerosis. Arthritis & Rheumatology 72(7):1160\u20131169","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"2424_CR15","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jid.2021.02.015","volume":"141","author":"Y Ototake","year":"2021","unstructured":"Ototake Y et al (2021) Downregulated IRF8 in monocytes and macrophages of patients with systemic sclerosis may aggravate the fibrotic phenotype. J Invest Dermatol 141(8):1954\u20131963","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2424_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12931-018-0891-z","volume":"19","author":"AC Trombetta","year":"2018","unstructured":"Trombetta AC et al (2018) A circulating cell population showing both M1 and M2 monocyte\/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res 19(1):186","journal-title":"Respir Res"},{"issue":"6","key":"2424_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","volume":"76","author":"C Maier","year":"2017","unstructured":"Maier C et al (2017) Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis 76(6):1133\u20131141","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2424_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/BOR.0000000000000542","volume":"30","author":"M Brown","year":"2018","unstructured":"Brown M, O\u2019Reilly S (2018) Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: advances and opportunities for therapy. Curr Opin Rheumatol 30(6):600\u2013605","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"2424_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/annrheumdis-2012-201958","volume":"72","author":"M Ciechomska","year":"2013","unstructured":"Ciechomska M et al (2013) Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis 72(8):1382","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2424_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","volume":"37","author":"N Fullard","year":"2015","unstructured":"Fullard N, O\u2019Reilly S (2015) Role of innate immune system in systemic sclerosis. Seminars in Immunopathology 37(5):511\u2013517","journal-title":"Seminars in Immunopathology"},{"key":"2424_CR21","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S et al (2016) Tenascin-C drives persistence of organ fibrosis. Nat Commun 7:11703","journal-title":"Nat Commun"},{"issue":"1","key":"2424_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110820","volume":"10","author":"K Lakota","year":"2015","unstructured":"Lakota K et al (2015) Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. PLoS ONE 10(1):e0110820","journal-title":"PLoS ONE"},{"issue":"232","key":"2424_CR23","doi-asserted-by":"publisher","first-page":"232ra50","DOI":"10.1126\/scitranslmed.3008264","volume":"6","author":"S Bhattacharyya","year":"2014","unstructured":"Bhattacharyya S et al (2014) FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 6(232):232ra50","journal-title":"Sci Transl Med"},{"issue":"3","key":"2424_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"9","key":"2424_CR25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/art.41737","volume":"73","author":"M Rudnik","year":"2021","unstructured":"Rudnik M et al (2021) Regulation of monocyte adhesion and type i interferon signaling by CD52 in patients with systemic sclerosis. Arthritis Rheumatol 73(9):1720\u20131730","journal-title":"Arthritis Rheumatol"},{"key":"2424_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fimmu.2019.00100","volume":"10","author":"B Mariotti","year":"2019","unstructured":"Mariotti B et al (2019) The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis. Front Immunol 10:100","journal-title":"Front Immunol"},{"issue":"9","key":"2424_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, H\u00fcgle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology 51(9):1540\u20131549","journal-title":"Rheumatology"},{"issue":"4","key":"2424_CR28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL (2019) The IL-17 family of cytokines in health and disease. Immunity 50(4):892\u2013906","journal-title":"Immunity"},{"issue":"3","key":"2424_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5493\/wjem.v7.i3.84","volume":"7","author":"E Krasimirova","year":"2017","unstructured":"Krasimirova E et al (2017) Treg\/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients. World J Exp Med 7(3):84\u201396","journal-title":"World J Exp Med"},{"issue":"8","key":"2424_CR30","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","volume":"188","author":"T Nakashima","year":"2012","unstructured":"Nakashima T et al (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188(8):3573\u20133583","journal-title":"J Immunol"},{"issue":"2","key":"2424_CR31","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M et al (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24(2):328\u2013332","journal-title":"J Rheumatol"},{"issue":"1","key":"2424_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/art.37706","volume":"65","author":"P Fuschiotti","year":"2013","unstructured":"Fuschiotti P et al (2013) Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 65(1):236\u2013246","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2424_CR33","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1172\/JCI131700","volume":"130","author":"T Maehara","year":"2020","unstructured":"Maehara T et al (2020) Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130(5):2451\u20132464","journal-title":"J Clin Invest"},{"key":"2424_CR34","first-page":"kead273","volume":"13","author":"CM Padila","year":"2023","unstructured":"Padila CM et al (2023) Increased CD8+ tissue resident memory T cells, regulatory T cells, and activated natural killer cells in systemic sclerosis lungs. Rheumatology 13:kead273","journal-title":"Rheumatology"},{"issue":"12","key":"2424_CR35","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","volume":"79","author":"Y Allanore","year":"2020","unstructured":"Allanore Y et al (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79(12):1600\u20131607","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2424_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED (2017) Abatacept: a review in rheumatoid arthritis. Drugs 77(11):1221\u20131233","journal-title":"Drugs"},{"issue":"12","key":"2424_CR37","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","volume":"2","author":"L Chung","year":"2020","unstructured":"Chung L et al (2020) Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol 2(12):e743\u2013e753","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"2424_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y et al (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133\u2013145","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2424_CR39","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA et al (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318\u2013328","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2424_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S et al (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77(5):521\u2013546","journal-title":"Drugs"},{"issue":"1","key":"2424_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2397198319865367","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang W et al (2020) The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord 5(1):40\u201350","journal-title":"J Scleroderma Relat Disord"},{"issue":"14","key":"2424_CR42","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O'Reilly","year":"2014","unstructured":"O\u2019Reilly S et al (2014) Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 289(14):9952\u20139960","journal-title":"J Biol Chem"},{"issue":"7","key":"2424_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan K et al (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71(7):1235","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2424_CR44","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8(1):1130","journal-title":"Nat Commun"},{"key":"2424_CR45","doi-asserted-by":"publisher","first-page":"adv4805","DOI":"10.2340\/actadv.v103.4805","volume":"103","author":"JC Tang","year":"2023","unstructured":"Tang JC et al (2023) Successful treatment of paediatric morphea with tofacitinib. Acta Derm Venereol 103:adv4805","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2424_CR46","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","volume":"60","author":"H You","year":"2021","unstructured":"You H et al (2021) Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 60(5):2472\u20132477","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2424_CR47","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","volume":"41","author":"RV Karalilova","year":"2021","unstructured":"Karalilova RV et al (2021) Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int 41(10):1743\u20131753","journal-title":"Rheumatol Int"},{"key":"2424_CR48","doi-asserted-by":"crossref","unstructured":"Khanna D et al (2022) Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight 7(17):e159566.","DOI":"10.1172\/jci.insight.159566"},{"key":"2424_CR49","doi-asserted-by":"crossref","unstructured":"O'Reilly S (2023) Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis. Clin Exp Immunol uxad077","DOI":"10.1093\/cei\/uxad077"},{"key":"2424_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109723","volume":"116","author":"N Bellamri","year":"2023","unstructured":"Bellamri N et al (2023) Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis. Int Immunopharmacol 116:109723","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"2424_CR51","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","volume":"76","author":"Y Zhang","year":"2017","unstructured":"Zhang Y et al (2017) JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann Rheum Dis 76(8):1467\u20131475","journal-title":"Ann Rheum Dis"},{"key":"2424_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A et al (2020) Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 178:114103","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2424_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","volume":"78","author":"L Ricard","year":"2019","unstructured":"Ricard L et al (2019) Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis 78(4):539\u2013550","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2424_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42358-023-00325-z","volume":"63","author":"H Liu","year":"2023","unstructured":"Liu H et al (2023) Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2\/Stat3 signaling pathway. Adv Rheumatol 63(1):45","journal-title":"Adv Rheumatol"},{"key":"2424_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859330","volume":"9","author":"Z Hou","year":"2022","unstructured":"Hou Z et al (2022) JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front Med (Lausanne) 9:859330","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2424_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-016-1213-9","volume":"19","author":"O Aravena","year":"2017","unstructured":"Aravena O et al (2017) TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. Arthritis Res Ther 19(1):8","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2424_CR57","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","volume":"127","author":"T Matsushita","year":"2007","unstructured":"Matsushita T et al (2007) BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 127(12):2772\u20132780","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2424_CR58","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825\u20132833","journal-title":"J Clin Oncol"},{"issue":"6","key":"2424_CR59","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2008.092791","volume":"68","author":"YK Teng","year":"2009","unstructured":"Teng YK et al (2009) Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68(6):1011\u20131016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2424_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123","journal-title":"Semin Hematol"},{"issue":"7","key":"2424_CR61","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. The Lancet Rheumatology 3(7):e489\u2013e497","journal-title":"The Lancet Rheumatology"},{"issue":"7","key":"2424_CR62","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/imj.15832","volume":"53","author":"K Morgan","year":"2023","unstructured":"Morgan K et al (2023) Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients. Intern Med J 53(7):1147\u20131153","journal-title":"Intern Med J"},{"issue":"6","key":"2424_CR63","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M et al (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17(6):582\u2013587","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2424_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2424_CR65","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V et al (2017) Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) 56(7):1227\u20131237","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2424_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA et al (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"2424_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686483","volume":"12","author":"D Simon","year":"2021","unstructured":"Simon D et al (2021) Increased frequency of activated switched memory B cells and its association with the presence of pulmonary fibrosis in diffuse cutaneous systemic sclerosis patients. Front Immunol 12:686483","journal-title":"Front Immunol"},{"issue":"2","key":"2424_CR68","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","volume":"55","author":"T Matsushita","year":"2015","unstructured":"Matsushita T et al (2015) Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology 55(2):263\u2013267","journal-title":"Rheumatology"},{"issue":"8","key":"2424_CR69","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"2424_CR70","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"key":"2424_CR71","first-page":"1117","volume-title":"Ann Rheum Dis","author":"C Bergmann","year":"2023","unstructured":"Bergmann C et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. England, pp 1117\u20131120"},{"issue":"26","key":"2424_CR72","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330","journal-title":"Blood"},{"issue":"4","key":"2424_CR73","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330\u2013340","journal-title":"N Engl J Med"},{"issue":"5","key":"2424_CR74","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1002\/hep.31987","volume":"74","author":"W Yang","year":"2021","unstructured":"Yang W et al (2021) Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology 74(5):2774\u20132790","journal-title":"Hepatology"},{"issue":"8","key":"2424_CR75","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","volume":"74","author":"C Dees","year":"2015","unstructured":"Dees C et al (2015) Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 74(8):1621\u20131625","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2424_CR76","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D et al (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79(5):618\u2013625","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2424_CR77","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","volume":"334","author":"PC Heinrich","year":"1998","unstructured":"Heinrich PC et al (1998) Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J 334(2):297\u2013314","journal-title":"Biochem J"},{"issue":"7683","key":"2424_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer S et al (2017) IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552(7683):110\u2013115","journal-title":"Nature"},{"issue":"1","key":"2424_CR79","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","volume":"12","author":"J Dong","year":"2021","unstructured":"Dong J et al (2021) Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH. Nat Commun 12(1):66","journal-title":"Nat Commun"},{"issue":"1","key":"2424_CR80","doi-asserted-by":"publisher","first-page":"17853","DOI":"10.1038\/s41598-020-74944-7","volume":"10","author":"WW Lim","year":"2020","unstructured":"Lim WW et al (2020) Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models. Sci Rep 10(1):17853","journal-title":"Sci Rep"},{"key":"2424_CR81","doi-asserted-by":"crossref","unstructured":"Ng B et al (2019) Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med 11(511)","DOI":"10.1126\/scitranslmed.aaw1237"},{"issue":"9","key":"2424_CR82","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1096\/fj.202001045RR","volume":"34","author":"B Ng","year":"2020","unstructured":"Ng B et al (2020) Fibroblast-specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease. Faseb j 34(9):11802\u201311815","journal-title":"Faseb j"},{"key":"2424_CR83","doi-asserted-by":"crossref","unstructured":"Sweeney M et al (2023) Cardiomyocyte-restricted expression of IL11 causes cardiac fibrosis, inflammation, and dysfunction. Int J Mol Sci 24(16)","DOI":"10.3390\/ijms241612989"},{"key":"2424_CR84","doi-asserted-by":"crossref","unstructured":"Adami E et al (2021) IL11 is elevated in systemic sclerosis and IL11-dependent ERK signaling underlies TGF\u03b2-mediated activation of dermal fibroblasts. Rheumatology (Oxford)","DOI":"10.1093\/rheumatology\/keab168"},{"key":"2424_CR85","doi-asserted-by":"crossref","unstructured":"Steadman T, O\u2019Reilly S (2023) Elevated interleukin-11 in systemic sclerosis and role in disease pathogenesis. J Dermatol","DOI":"10.1111\/1346-8138.16854"},{"issue":"10","key":"2424_CR86","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/1346-8138.16854","volume":"50","author":"T Steadman","year":"2023","unstructured":"Steadman T, O\u2019Reilly S (2023) Elevated interleukin-11 in systemic sclerosis and role in disease pathogenesis. J Dermatol 50(10):1255\u20131261","journal-title":"J Dermatol"},{"issue":"6","key":"2424_CR87","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/08820139.2023.2222746","volume":"52","author":"W Ye","year":"2023","unstructured":"Ye W et al (2023) Blockade of IL-11 trans-signaling or JAK2\/STAT3 signaling ameliorates the profibrotic effect of IL-11. Immunol Invest 52(6):703\u2013716","journal-title":"Immunol Invest"},{"issue":"25","key":"2424_CR88","doi-asserted-by":"publisher","first-page":"eabn7162","DOI":"10.1126\/sciadv.abn7162","volume":"8","author":"X Bai","year":"2022","unstructured":"Bai X et al (2022) Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv 8(25):eabn7162","journal-title":"Sci Adv"},{"issue":"3","key":"2424_CR89","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","volume":"141","author":"IS Ba\u011fci","year":"2018","unstructured":"Ba\u011fci IS, Ruzicka T (2018) IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol 141(3):858\u2013866","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2424_CR90","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","volume":"117","author":"J Bilsborough","year":"2006","unstructured":"Bilsborough J et al (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117(2):418\u2013425","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2424_CR91","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen B et al (2020) Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology (Oxford) 59(9):2625\u20132636","journal-title":"Rheumatology (Oxford)"},{"key":"2424_CR92","doi-asserted-by":"crossref","unstructured":"Corano Scheri K et al (2022) SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma. JCI Insight 7(21)","DOI":"10.1172\/jci.insight.160977"},{"issue":"4","key":"2424_CR93","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K et al (2022) Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 186(4):642\u2013651","journal-title":"Br J Dermatol"},{"issue":"3","key":"2424_CR94","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/1756-185X.13769","volume":"23","author":"Y Lu","year":"2020","unstructured":"Lu Y et al (2020) Effects of thalidomide on Th17, Treg cells and TGF-\u03b21\/Smad3 pathway in a mouse model of systemic sclerosis. Int J Rheum Dis 23(3):406\u2013419","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"2424_CR95","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/23971983231180077","volume":"8","author":"J Pan","year":"2023","unstructured":"Pan J et al (2023) Therapeutic effects of thalidomide on patients with systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord 8(3):231\u2013240","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"2424_CR96","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","volume":"45","author":"MH Vivien","year":"2018","unstructured":"Vivien MH et al (2018) Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Rheumatol 45(3):405","journal-title":"J Rheumatol"},{"key":"2424_CR97","doi-asserted-by":"crossref","unstructured":"Odell ID et al (2022) Epiregulin is a dendritic cell\u2013derived EGFR ligand that maintains skin and lung fibrosis. Sci Immunol 7(78):eabq6691","DOI":"10.1126\/sciimmunol.abq6691"},{"key":"2424_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.591246","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu X et al (2020) Epiregulin (EREG) and myocardin related transcription factor A (MRTF-A) form a feedforward loop to drive hepatic stellate cell activation. Front Cell Dev Biol 8:591246","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"2424_CR99","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ncb3586","volume":"19","author":"S Gl\u00fcck","year":"2017","unstructured":"Gl\u00fcck S et al (2017) Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol 19(9):1061\u20131070","journal-title":"Nat Cell Biol"},{"issue":"11","key":"2424_CR100","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/art.41418","volume":"72","author":"C Ryu","year":"2020","unstructured":"Ryu C et al (2020) Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease. Arthritis Rheumatol 72(11):1905\u20131915","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2424_CR101","doi-asserted-by":"publisher","first-page":"7074","DOI":"10.1038\/s41467-022-34775-8","volume":"13","author":"S Paul","year":"2022","unstructured":"Paul S et al (2022) Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis. Nat Commun 13(1):7074","journal-title":"Nat Commun"},{"issue":"2","key":"2424_CR102","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/rheumatology\/keac324","volume":"62","author":"C Liu","year":"2023","unstructured":"Liu C et al (2023) DNA from macrophages induces fibrosis and vasculopathy through POLR3A\/STING\/type I interferon axis in systemic sclerosis. Rheumatology (Oxford) 62(2):934\u2013945","journal-title":"Rheumatology (Oxford)"},{"issue":"24","key":"2424_CR103","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1111\/bph.15673","volume":"178","author":"Y Pan","year":"2021","unstructured":"Pan Y et al (2021) The STING antagonist H-151 ameliorates psoriasis via suppression of STING\/NF-\u03baB-mediated inflammation. Br J Pharmacol 178(24):4907\u20134922","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2424_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284061","volume":"18","author":"B Mdkhana","year":"2023","unstructured":"Mdkhana B et al (2023) Nucleic acid sensor STING drives remodeling and its inhibition enhances steroid responsiveness in chronic obstructive pulmonary disease. PLoS ONE 18(7):e0284061","journal-title":"PLoS ONE"},{"issue":"4","key":"2424_CR105","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41422-020-0291-z","volume":"30","author":"EM P\u00e5lsson-McDermott","year":"2020","unstructured":"P\u00e5lsson-McDermott EM, O\u2019Neill LAJ (2020) Targeting immunometabolism as an anti-inflammatory strategy. Cell Res 30(4):300\u2013314","journal-title":"Cell Res"},{"key":"2424_CR106","doi-asserted-by":"crossref","unstructured":"Henderson J et al (2020) Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. J Cell Mol Med","DOI":"10.1111\/jcmm.16013"},{"key":"2424_CR107","doi-asserted-by":"publisher","first-page":"1004949","DOI":"10.3389\/fimmu.2022.1004949","volume":"13","author":"IG Cantanhede","year":"2022","unstructured":"Cantanhede IG et al (2022) Exploring metabolism in scleroderma reveals opportunities for pharmacological intervention for therapy in fibrosis. Front Immunol 13:1004949","journal-title":"Front Immunol"},{"issue":"Pt 3","key":"2424_CR108","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker RA et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3):678\u2013692","journal-title":"Brain"},{"issue":"6387","key":"2424_CR109","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg MD et al (2018) Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 360(6387):449\u2013453","journal-title":"Science"},{"issue":"1","key":"2424_CR110","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jid.2017.08.024","volume":"138","author":"T Toyama","year":"2018","unstructured":"Toyama T et al (2018) Therapeutic targeting of tAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J Invest Dermatol 138(1):78\u201388","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2424_CR111","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/23971983211016196","volume":"6","author":"K Kong","year":"2021","unstructured":"Kong K et al (2021) A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis. J Scleroderma Relat Disord 6(3):242\u2013246","journal-title":"J Scleroderma Relat Disord"},{"issue":"7699","key":"2424_CR112","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature25986","volume":"556","author":"EL Mills","year":"2018","unstructured":"Mills EL et al (2018) Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556(7699):113\u2013117","journal-title":"Nature"},{"issue":"52","key":"2424_CR113","doi-asserted-by":"publisher","first-page":"eabc1884","DOI":"10.1126\/sciimmunol.abc1884","volume":"5","author":"PP Ogger","year":"2020","unstructured":"Ogger PP et al (2020) Itaconate controls the severity of pulmonary fibrosis. Sci Immunol 5(52):eabc1884","journal-title":"Sci Immunol"},{"key":"2424_CR114","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbrc.2022.03.110","volume":"607","author":"K Fan","year":"2022","unstructured":"Fan K et al (2022) Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice. Biochem Biophys Res Commun 607:103\u2013109","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2424_CR115","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cmet.2022.02.002","volume":"34","author":"MC Runtsch","year":"2022","unstructured":"Runtsch MC et al (2022) Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. Cell Metab 34(3):487-501.e8","journal-title":"Cell Metab"},{"issue":"4","key":"2424_CR116","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/imm.13454","volume":"165","author":"C Hoyle","year":"2022","unstructured":"Hoyle C et al (2022) Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages. Immunology 165(4):460\u2013480","journal-title":"Immunology"},{"issue":"3","key":"2424_CR117","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jdermsci.2022.12.006","volume":"108","author":"C Liu","year":"2022","unstructured":"Liu C et al (2022) Cathepsin B\/NLRP3\/GSDMD axis-mediated macrophage pyroptosis induces inflammation and fibrosis in systemic sclerosis. J Dermatol Sci 108(3):127\u2013137","journal-title":"J Dermatol Sci"},{"issue":"Pt B","key":"2424_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110915","volume":"124","author":"M You","year":"2023","unstructured":"You M et al (2023) 4-Octyl itaconate inhibits inflammation to attenuate psoriasis as an agonist of oxeiptosis. Int Immunopharmacol 124(Pt B):110915","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2424_CR119","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2020.04.015","volume":"32","author":"LP Bharath","year":"2020","unstructured":"Bharath LP et al (2020) Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab 32(1):44-55.e6","journal-title":"Cell Metab"},{"issue":"8","key":"2424_CR120","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41591-018-0087-6","volume":"24","author":"S Rangarajan","year":"2018","unstructured":"Rangarajan S et al (2018) Metformin reverses established lung fibrosis in a bleomycin model. Nat Med 24(8):1121\u20131127","journal-title":"Nat Med"},{"key":"2424_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2023.106375","volume":"157","author":"Y Su","year":"2023","unstructured":"Su Y et al (2023) Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis. Int J Biochem Cell Biol 157:106375","journal-title":"Int J Biochem Cell Biol"},{"key":"2424_CR122","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.mce.2015.06.006","volume":"412","author":"RC Cavaglieri","year":"2015","unstructured":"Cavaglieri RC et al (2015) Metformin prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. Mol Cell Endocrinol 412:116\u2013122","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"2424_CR123","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.jid.2016.05.097","volume":"136","author":"F Ursini","year":"2016","unstructured":"Ursini F et al (2016) Oral metformin ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 136(9):1892\u20131894","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2424_CR124","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1038\/s41598-022-06581-1","volume":"12","author":"A Karatas","year":"2022","unstructured":"Karatas A et al (2022) Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. Sci Rep 12(1):2553","journal-title":"Sci Rep"},{"key":"2424_CR125","doi-asserted-by":"publisher","first-page":"1089812","DOI":"10.3389\/fphar.2023.1089812","volume":"14","author":"H Ji","year":"2023","unstructured":"Ji H et al (2023) Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK-STAT3 axis. Front Pharmacol 14:1089812","journal-title":"Front Pharmacol"},{"key":"2424_CR126","doi-asserted-by":"crossref","unstructured":"\u0160vec X et al (2023) S100A4 neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin. Rheumatology (Oxford)","DOI":"10.1093\/rheumatology\/kead295"},{"key":"2424_CR127","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molimm.2019.07.002","volume":"114","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg\/Teff cells and reducing spleen germinal center formation. Mol Immunol 114:72\u201380","journal-title":"Mol Immunol"},{"key":"2424_CR128","doi-asserted-by":"crossref","unstructured":"Shi B et al (2021) Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis. iScience 24(1):101902","DOI":"10.1016\/j.isci.2020.101902"},{"issue":"10027","key":"2424_CR129","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S et al (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551\u20131560","journal-title":"Lancet"},{"issue":"5","key":"2424_CR130","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV et al (2020) Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 7(5):e370\u2013e380","journal-title":"Lancet Haematol"},{"key":"2424_CR131","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ (2018) CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol 9:2134","journal-title":"Front Immunol"},{"key":"2424_CR132","unstructured":"Shi B et al (2022) Senescent cells accumulate in systemic sclerosis skin. J Invest Dermatol"},{"issue":"3","key":"2424_CR133","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","volume":"123","author":"T Tchkonia","year":"2013","unstructured":"Tchkonia T et al (2013) Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123(3):966\u2013972","journal-title":"J Clin Invest"},{"key":"2424_CR134","first-page":"17","volume":"38","author":"MC Velarde","year":"2013","unstructured":"Velarde MC, Demaria M, Campisi J (2013) Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 38:17\u201327","journal-title":"Interdiscip Top Gerontol"},{"issue":"1","key":"2424_CR135","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1038\/ncomms14532","volume":"8","author":"MJ Schafer","year":"2017","unstructured":"Schafer MJ et al (2017) Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 8(1):14532","journal-title":"Nat Commun"},{"key":"2424_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102847","volume":"131","author":"R Gniadecki","year":"2022","unstructured":"Gniadecki R et al (2022) Genomic instability in early systemic sclerosis. J Autoimmun 131:102847","journal-title":"J Autoimmun"},{"key":"2424_CR137","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"JN Justice","year":"2019","unstructured":"Justice JN et al (2019) Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40:554\u2013563","journal-title":"EBioMedicine"},{"issue":"1","key":"2424_CR138","doi-asserted-by":"publisher","first-page":"L29","DOI":"10.1152\/ajplung.00173.2020","volume":"320","author":"XX Nguyen","year":"2021","unstructured":"Nguyen XX et al (2021) Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. Am J Physiol Lung Cell Mol Physiol 320(1):L29-l40","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"2424_CR139","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/rheumatology\/kez035","volume":"58","author":"Z Vadasz","year":"2019","unstructured":"Vadasz Z et al (2019) Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. Rheumatology (Oxford) 58(9):1547\u20131555","journal-title":"Rheumatology (Oxford)"},{"key":"2424_CR140","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.matbio.2019.03.002","volume":"82","author":"NE Calabro","year":"2019","unstructured":"Calabro NE et al (2019) Thrombospondin-2 regulates extracellular matrix production, LOX levels, and cross-linking via downregulation of miR-29. Matrix Biol 82:71\u201385","journal-title":"Matrix Biol"},{"issue":"3","key":"2424_CR141","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/0168-8278(91)90006-W","volume":"13","author":"K B\u00f6ker","year":"1991","unstructured":"B\u00f6ker K et al (1991) Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition by prolyl 4-hydroxylase. J Hepatol 13(3):S35-40","journal-title":"J Hepatol"},{"issue":"2","key":"2424_CR142","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001564RR","volume":"35","author":"N Smith-Cortinez","year":"2021","unstructured":"Smith-Cortinez N et al (2021) Collagen release by human hepatic stellate cells requires vitamin C and is efficiently blocked by hydroxylase inhibition. Faseb j 35(2):e21219","journal-title":"Faseb j"},{"issue":"47","key":"2424_CR143","doi-asserted-by":"publisher","first-page":"28465","DOI":"10.1074\/jbc.M114.634311","volume":"290","author":"RAF Gjaltema","year":"2015","unstructured":"Gjaltema RAF et al (2015) Procollagen lysyl hydroxylase 2 expression is regulated by an alternative downstream transforming growth factor \u03b2-1 activation mechanism *. J Biol Chem 290(47):28465\u201328476","journal-title":"J Biol Chem"},{"issue":"7","key":"2424_CR144","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.matbio.2005.07.002","volume":"24","author":"J Brinckmann","year":"2005","unstructured":"Brinckmann J et al (2005) Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol 24(7):459\u2013468","journal-title":"Matrix Biol"},{"issue":"3","key":"2424_CR145","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1021\/acs.jcim.2c01448","volume":"63","author":"Y Maghsoud","year":"2023","unstructured":"Maghsoud Y et al (2023) Computational investigation of a series of small molecules as potential compounds for lysyl hydroxylase-2 (LH2) inhibition. J Chem Inf Model 63(3):986\u20131001","journal-title":"J Chem Inf Model"},{"key":"2424_CR146","doi-asserted-by":"crossref","unstructured":"Werner G et al (2023) Single-cell transcriptome analysis identifies subclusters with inflammatory fibroblast responses in localized scleroderma. Int J Mol Sci\u00a0 24(12)","DOI":"10.3390\/ijms24129796"},{"issue":"8","key":"2424_CR147","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2022.03.011","volume":"185","author":"C Gur","year":"2022","unstructured":"Gur C et al (2022) LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma. Cell 185(8):1373-1388.e20","journal-title":"Cell"},{"key":"2424_CR148","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lfs.2015.01.042","volume":"127","author":"J Lu","year":"2015","unstructured":"Lu J et al (2015) Activation of AMPK by metformin inhibits TGF-\u03b2-induced collagen production in mouse renal fibroblasts. Life Sci 127:59\u201365","journal-title":"Life Sci"},{"key":"2424_CR149","doi-asserted-by":"crossref","unstructured":"Corremans R et al (2023) Metformin and canagliflozin are equally renoprotective in diabetic kidney disease but have no synergistic effect. Int J Mol Sci 24(10)","DOI":"10.3390\/ijms24109043"},{"key":"2424_CR150","doi-asserted-by":"crossref","unstructured":"Widjaja AA et al (2022) IL11 stimulates ERK\/P90RSK to inhibit LKB1\/AMPK and activate mTOR initiating a mesenchymal program in stromal, epithelial, and cancer cells. iScience 25(8):104806","DOI":"10.1016\/j.isci.2022.104806"},{"key":"2424_CR151","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jot.2023.05.011","volume":"40","author":"Z Zhu","year":"2023","unstructured":"Zhu Z et al (2023) Metformin improves fibroblast metabolism and ameliorates arthrofibrosis in rats. J Orthop Translat 40:92\u2013103","journal-title":"J Orthop Translat"},{"issue":"7","key":"2424_CR152","doi-asserted-by":"publisher","first-page":"960","DOI":"10.7150\/ijms.32157","volume":"16","author":"R Lei","year":"2019","unstructured":"Lei R et al (2019) Metformin inhibits epithelial-to-mesenchymal transition of keloid fibroblasts via the HIF-1\u03b1\/PKM2 signaling pathway. Int J Med Sci 16(7):960\u2013966","journal-title":"Int J Med Sci"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-024-02424-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T07:03:39Z","timestamp":1711350219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-024-02424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2424"],"URL":"https:\/\/doi.org\/10.1007\/s00109-024-02424-w","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}